Annual Reports

 
Other

  • 6-K (Sep 2, 2014)
  • 6-K (Jun 18, 2014)
  • 6-K (Jun 2, 2014)
  • 6-K (May 19, 2014)
  • EFFECT (Apr 4, 2014)
  • CORRESP (Apr 3, 2014)
XTL Biopharmaceuticals 6-K 2012

Documents found in this filing:

  1. 6-K
  2. Graphic
  3. Graphic

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

 

For the month of May, 2012

 

Commission File Number: 000-51310

 

XTL Biopharmaceuticals Ltd.

 

(Translation of registrant’s name into English)

 

85 Medinat Hayehudim St., Herzliya
Pituach, PO Box 4033,
Herzliya 46140, Israel

 

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x        Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨        No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

 

 

 

 
 

 

Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated May 22, 2012 is hereby incorporated by reference into the registration statements on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the registration statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.

 

XTL Biopharmaceuticals Ltd. Extraordinary General Meeting Postponed Until May 29, 2012

 

Below is a summary English translation (from Hebrew) of a report by XTL Biopharmaceuticals Ltd.

 

 

Herzliya, Israel – May 22, 2012 – XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (hereinafter, “XTL”), announced today that its Extraordinary General Meeting (“EGM”) was postponed for one week in accordance with its articles of association due to the absence of a quorum. The postponed EGM will take place at Kantor and Co. Law Offices, 12 Abba Hillel Silver St., 8th floor, Ramat Gan, Israel at 10:30 AM Israel time on May 29, 2012.

 

Any proxy votes received at any time up to 48 hours prior to the postponed EGM will be included in the total votes counted for the EGM. Those shareholders who have a valid “proof of ownership”, or a letter of representation from the Bank of New York Mellon for an ADR owner, and attend the meeting in person will also be permitted to vote.

 

 

Contact:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: +972 9 955 7080, Email: ir@xtlbio.com

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

  XTL BIOPHARMACEUTICALS LTD.
   
   
Date: May 22, 2012 By:  /s/ David Grossman
    Name:    David Grossman
Title:      Chief Executive Officer

 

 
 

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki